BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Capece D, Verzella D, Fischietti M, Zazzeroni F, Alesse E. Targeting costimulatory molecules to improve antitumor immunity. J Biomed Biotechnol 2012;2012:926321. [PMID: 22500111 DOI: 10.1155/2012/926321] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Amoroso M, Langgartner D, Lowry CA, Reber SO. Rapidly Growing Mycobacterium Species: The Long and Winding Road from Tuberculosis Vaccines to Potent Stress-Resilience Agents. Int J Mol Sci 2021;22:12938. [PMID: 34884743 DOI: 10.3390/ijms222312938] [Reference Citation Analysis]
2 Dacoba TG, Anthiya S, Berrecoso G, Fernández‐mariño I, Fernández‐varela C, Crecente‐campo J, Teijeiro‐osorio D, Torres Andón F, Alonso MJ. Nano‐Oncologicals: A Tortoise Trail Reaching New Avenues. Adv Funct Mater 2021;31:2009860. [DOI: 10.1002/adfm.202009860] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
3 Somasundaram R, Herlyn M. Nivolumab in combination with ipilimumab for the treatment of melanoma. Expert Rev Anticancer Ther 2015;15:1135-41. [PMID: 26402246 DOI: 10.1586/14737140.2015.1093418] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
4 Sahraei M, Chaube B, Liu Y, Sun J, Kaplan A, Price NL, Ding W, Oyaghire S, García-Milian R, Mehta S, Reshetnyak YK, Bahal R, Fiorina P, Glazer PM, Rimm DL, Fernández-Hernando C, Suárez Y. Suppressing miR-21 activity in tumor-associated macrophages promotes an antitumor immune response. J Clin Invest 2019;129:5518-36. [PMID: 31710308 DOI: 10.1172/JCI127125] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 18.0] [Reference Citation Analysis]
5 Kartikasari AER, Prakash MD, Cox M, Wilson K, Boer JC, Cauchi JA, Plebanski M. Therapeutic Cancer Vaccines-T Cell Responses and Epigenetic Modulation. Front Immunol 2018;9:3109. [PMID: 30740111 DOI: 10.3389/fimmu.2018.03109] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
6 Cook K, Durrant L, Brentville V. Current Strategies to Enhance Anti-Tumour Immunity. Biomedicines 2018;6:37. [DOI: 10.3390/biomedicines6020037] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
7 Willemsen M, Melief CJM, Bekkenk MW, Luiten RM. Targeting the PD-1/PD-L1 Axis in Human Vitiligo. Front Immunol 2020;11:579022. [PMID: 33240267 DOI: 10.3389/fimmu.2020.579022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Du G, Liu Y, Li J, Liu W, Wang Y, Li H. Hypothermic microenvironment plays a key role in tumor immune subversion. International Immunopharmacology 2013;17:245-53. [DOI: 10.1016/j.intimp.2013.06.018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
9 Carter CA, Oronsky BT, Roswarski J, Oronsky AL, Oronsky N, Scicinski J, Lybeck H, Kim MM, Lybeck M, Reid TR. No patient left behind: The promise of immune priming with epigenetic agents. Oncoimmunology 2017;6:e1315486. [PMID: 29123948 DOI: 10.1080/2162402X.2017.1315486] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
10 O'Neill RE, Cao X. Co-stimulatory and co-inhibitory pathways in cancer immunotherapy. Adv Cancer Res 2019;143:145-94. [PMID: 31202358 DOI: 10.1016/bs.acr.2019.03.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
11 Dieu-Nosjean MC, Giraldo NA, Kaplon H, Germain C, Fridman WH, Sautès-Fridman C. Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. Immunol Rev 2016;271:260-75. [PMID: 27088920 DOI: 10.1111/imr.12405] [Cited by in Crossref: 134] [Cited by in F6Publishing: 132] [Article Influence: 22.3] [Reference Citation Analysis]
12 Vasaturo A, Di Blasio S, Peeters DG, de Koning CC, de Vries JM, Figdor CG, Hato SV. Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go. Front Immunol 2013;4:417. [PMID: 24348481 DOI: 10.3389/fimmu.2013.00417] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 5.2] [Reference Citation Analysis]
13 Hewitt SL, Bai A, Bailey D, Ichikawa K, Zielinski J, Karp R, Apte A, Arnold K, Zacharek SJ, Iliou MS, Bhatt K, Garnaas M, Musenge F, Davis A, Khatwani N, Su SV, MacLean G, Farlow SJ, Burke K, Frederick JP. Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs. Sci Transl Med 2019;11:eaat9143. [PMID: 30700577 DOI: 10.1126/scitranslmed.aat9143] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 26.0] [Reference Citation Analysis]
14 Yang L, Guo G, Niu XY, Liu J. Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme. Biomed Res Int 2015;2015:717530. [PMID: 26167495 DOI: 10.1155/2015/717530] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
15 Whitman E, Barber A. NKG2D receptor activation of NF-κB enhances inflammatory cytokine production in murine effector CD8(+) T cells. Mol Immunol 2015;63:268-78. [PMID: 25089028 DOI: 10.1016/j.molimm.2014.07.015] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
16 McBride DA, Kerr MD, Wai SL, Shah NJ. Applications of molecular engineering in T-cell-based immunotherapies. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2019;11:e1557. [PMID: 30972976 DOI: 10.1002/wnan.1557] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
17 McQueen B, Trace K, Whitman E, Bedsworth T, Barber A. Natural killer group 2D and CD28 receptors differentially activate mammalian/mechanistic target of rapamycin to alter murine effector CD8+ T-cell differentiation. Immunology 2016;147:305-20. [PMID: 26661515 DOI: 10.1111/imm.12563] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
18 Chai SJ, Fong SCY, Gan CP, Pua KC, Lim PVH, Lau SH, Zain RB, Abraham T, Ismail SM, Abdul Rahman ZA, Ponniah S, Patel V, Cheong SC, Lim KP. In vitro evaluation of dual-antigenic PV1 peptide vaccine in head and neck cancer patients. Hum Vaccin Immunother 2019;15:167-78. [PMID: 30193086 DOI: 10.1080/21645515.2018.1520584] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
19 Sharpe M, Mount N. Genetically modified T cells in cancer therapy: opportunities and challenges. Dis Model Mech 2015;8:337-50. [PMID: 26035842 DOI: 10.1242/dmm.018036] [Cited by in Crossref: 92] [Cited by in F6Publishing: 74] [Article Influence: 13.1] [Reference Citation Analysis]
20 Khedri M, Kooshki H, Taheri RA. Rapamycin attenuates gene expression of programmed cell death protein-ligand 1 and Foxp3 in the brain; a novel mechanism proposed for immunotherapy in the brain. Res Pharm Sci 2021;16:165-72. [PMID: 34084203 DOI: 10.4103/1735-5362.310523] [Reference Citation Analysis]
21 Fan MK, Qi LL, Zhang Q, Wang L. The Updated Status and Future Direction of Immunotherapy Targeting B7-H1/PD-1 in Osteosarcoma. Cancer Manag Res 2021;13:757-64. [PMID: 33536783 DOI: 10.2147/CMAR.S285560] [Reference Citation Analysis]
22 Tagawa M, Maekawa N, Konnai S, Takagi S. Evaluation of Costimulatory Molecules in Peripheral Blood Lymphocytes of Canine Patients with Histiocytic Sarcoma. PLoS One 2016;11:e0150030. [PMID: 26901565 DOI: 10.1371/journal.pone.0150030] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
23 Zhang M, Yin T, Lu Y, Feng H. The Application of Cytidyl Guanosyl Oligodeoxynucleotide Can Affect the Antitumor Immune Response Induced by a Combined Protocol of Cryoablation and Dendritic Cells in Lewis Lung Cancer Model. Med Sci Monit 2016;22:1309-17. [PMID: 27092689 DOI: 10.12659/msm.898194] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
24 Leach J, Morton JP, Sansom OJ. Neutrophils: Homing in on the myeloid mechanisms of metastasis. Mol Immunol 2019;110:69-76. [PMID: 29269005 DOI: 10.1016/j.molimm.2017.12.013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
25 Zhang Z, Huang Q, Yu L, Zhu D, Li Y, Xue Z, Hua Z, Luo X, Song Z, Lu C, Zhao T, Liu Y. The Role of miRNA in Tumor Immune Escape and miRNA-Based Therapeutic Strategies. Front Immunol 2022;12:807895. [DOI: 10.3389/fimmu.2021.807895] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Antczak A, Pastuszak-Lewandoska D, Górski P, Domańska D, Migdalska-Sęk M, Czarnecka K, Nawrot E, Kordiak J, Brzeziańska E. Ctla-4 expression and polymorphisms in lung tissue of patients with diagnosed non-small-cell lung cancer. Biomed Res Int 2013;2013:576486. [PMID: 23936819 DOI: 10.1155/2013/576486] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
27 Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14:561-584. [PMID: 26228759 DOI: 10.1038/nrd4591] [Cited by in Crossref: 715] [Cited by in F6Publishing: 687] [Article Influence: 102.1] [Reference Citation Analysis]
28 Steinel NC, Lee EM, Viggiano D, Capasso A, Lee MW. The renal adverse effects of cancer immunotherapy. J Nephrol 2020;33:467-81. [PMID: 31912436 DOI: 10.1007/s40620-019-00691-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
29 Lin E, Liu X, Liu Y, Zhang Z, Xie L, Tian K, Liu J, Yu Y. Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma. Front Immunol 2021;12:653358. [PMID: 33746989 DOI: 10.3389/fimmu.2021.653358] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Cicchelero L, de Rooster H, Sanders NN. Various ways to improve whole cancer cell vaccines. Expert Rev Vaccines 2014;13:721-35. [PMID: 24758597 DOI: 10.1586/14760584.2014.911093] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
31 Melendreras SG, Martínez-Camblor P, Menéndez A, Bravo-Mendoza C, González-Vidal A, Coto E, Díaz-Corte C, Ruiz-Ortega M, López-Larrea C, Suárez-Álvarez B. Soluble co-signaling molecules predict long-term graft outcome in kidney-transplanted patients. PLoS One 2014;9:e113396. [PMID: 25478957 DOI: 10.1371/journal.pone.0113396] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
32 Mineharu Y, Castro MG, Lowenstein PR, Sakai N, Miyamoto S. Dendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trials. Neurol Med Chir (Tokyo) 2013;53:741-54. [PMID: 24140772 DOI: 10.2176/nmc.ra2013-0234] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
33 Chen XJ, Shen J, Zhang GB, Chen WC. B7-H6 protein expression has no prognostic significance in human gastric carcinoma. Pathol Oncol Res 2014;20:203-7. [PMID: 24242703 DOI: 10.1007/s12253-013-9686-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
34 Timmerman J, Herbaux C, Ribrag V, Zelenetz AD, Houot R, Neelapu SS, Logan T, Lossos IS, Urba W, Salles G, Ramchandren R, Jacobson C, Godwin J, Carpio C, Lathers D, Liu Y, Neely J, Suryawanshi S, Koguchi Y, Levy R. Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. Am J Hematol 2020;95:510-20. [PMID: 32052473 DOI: 10.1002/ajh.25757] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
35 Talat Iqbal N, Hussain R. Non-specific immunity of BCG vaccine: A perspective of BCG immunotherapy. Trials in Vaccinology 2014;3:143-9. [DOI: 10.1016/j.trivac.2014.08.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
36 Khedri M, Samei A, Fasihi-Ramandi M, Taheri RA. The immunopathobiology of T cells in stress condition: a review. Cell Stress Chaperones 2020;25:743-52. [PMID: 32319022 DOI: 10.1007/s12192-020-01105-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
37 Munhoz J, Thomé R, Rostami A, Ishikawa LLW, Verinaud L, Rapôso C. The SNX-482 peptide from Hysterocrates gigas spider acts as an immunomodulatory molecule activating macrophages. Peptides 2021;146:170648. [PMID: 34537257 DOI: 10.1016/j.peptides.2021.170648] [Reference Citation Analysis]
38 Han L, Kong DK, Zheng MQ, Murikinati S, Ma C, Yuan P, Li L, Tian D, Cai Q, Ye C, Holden D, Park JH, Gao X, Thomas JL, Grutzendler J, Carson RE, Huang Y, Piepmeier JM, Zhou J. Increased Nanoparticle Delivery to Brain Tumors by Autocatalytic Priming for Improved Treatment and Imaging. ACS Nano 2016;10:4209-18. [PMID: 26967254 DOI: 10.1021/acsnano.5b07573] [Cited by in Crossref: 80] [Cited by in F6Publishing: 74] [Article Influence: 13.3] [Reference Citation Analysis]
39 Müller D. Antibody–Cytokine Fusion Proteins for Cancer Immunotherapy: An Update on Recent Developments. BioDrugs 2014;28:123-31. [DOI: 10.1007/s40259-013-0069-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
40 Zhao Y, Zheng Q, Jin L. The Role of B7 Family Molecules in Maternal-Fetal Immunity. Front Immunol 2020;11:458. [PMID: 32265918 DOI: 10.3389/fimmu.2020.00458] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
41 Li H, Zhou X, Ran Q, Wang L. Parapharyngeal liposarcoma: a case report. Diagn Pathol 2013;8:42. [PMID: 23497351 DOI: 10.1186/1746-1596-8-42] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
42 Chen D, Jaing T, Hour A, Lin W, Hsu F. Single-Nucleotide Polymorphisms Within Non-HLA Regions Are Associated With Engraftment Effectiveness for Patients With Unrelated Cord Blood Transplantation. Front Immunol 2022;13:888204. [DOI: 10.3389/fimmu.2022.888204] [Reference Citation Analysis]
43 Tian Y, Xie D, Yang L. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. Signal Transduct Target Ther 2022;7:117. [PMID: 35387984 DOI: 10.1038/s41392-022-00951-x] [Reference Citation Analysis]
44 Ban Y, Mai J, Li X, Mitchell-Flack M, Zhang T, Zhang L, Chouchane L, Ferrari M, Shen H, Ma X. Targeting Autocrine CCL5-CCR5 Axis Reprograms Immunosuppressive Myeloid Cells and Reinvigorates Antitumor Immunity. Cancer Res 2017;77:2857-68. [PMID: 28416485 DOI: 10.1158/0008-5472.CAN-16-2913] [Cited by in Crossref: 64] [Cited by in F6Publishing: 36] [Article Influence: 12.8] [Reference Citation Analysis]